Dermatology · Redding, CA
NPI
1952338907
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2107 Airpark Dr
Redding, CA, 96001
Phone (530) 241-7098
Groups this clinician bills Medicare through
Medicare paid, 2024
$272K
7,247 services
Medicare patients, 2024
1,633
Average age 75
Drug cost, 2024
$2.1M
1,033 prescriptions
Company payments, 2025
$2,122
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Brian A Reber was code 17003 (destruction skin lesion), 2,505 times for 455 patients. In total Brian A Reber billed 7,247 services in 82 codes, and Medicare paid $272K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-03-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 2,505 | 455 | $4.22 | $11K |
| 99213 Office E&M - Established | Office | 947 | 704 | $50.67 | $48K |
| 17000 Destruction Skin Lesion | Office | 813 | 620 | $31.13 | $25K |
| 99212 Office E&M - Established | Office | 624 | 522 | $30.92 | $19K |
| 17110 Destruction Skin Lesion | Office | 566 | 484 | $61.66 | $35K |
| 11102 Skin Biopsy | Office | 303 | 276 | $50.79 | $15K |
| 99203 Office E&M - New | Office | 225 | 225 | $54.65 | $12K |
| 99214 Office E&M - Established | Office | 165 | 147 | $70.46 | $12K |
| 99202 Office E&M - New | Office | 132 | 132 | $33.98 | $4,486 |
| 96910 Skin | Office | 124 | 13 | $81.13 | $10K |
| 17282 Destruction Skin Lesion | Office | 88 | 81 | $124.90 | $11K |
| 17262 Destruction Skin Lesion | Office | 87 | 75 | $102.25 | $8,896 |
| 11103 Skin Biopsy | Office | 66 | 54 | $30.79 | $2,032 |
| 99204 Office E&M - New | Office | 55 | 55 | $85.70 | $4,713 |
| 17281 Destruction Skin Lesion | Office | 51 | 48 | $106.68 | $5,440 |
By year: 2022 $259K for 6,589 services; 2023 $263K for 6,702 services; 2024 $272K for 7,247 services.
Medicare prescription drug claims, 2024
In 2024, the drug Brian A Reber prescribed most often to Medicare patients was Mometasone Furoate, with 142 prescriptions and refills. In total Brian A Reber wrote 1,033 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mometasone Furoate Generic | 142 | 144 | 103 | $2,203 |
| Taltz Autoinjector Ixekizumab | 117 | 121 | 11 | $820K |
| Doxycycline Hyclate Generic | 95 | 184 | 51 | $2,571 |
| Imiquimod Generic | 68 | 85 | 44 | $2,327 |
| Dupixent Pen Dupilumab | 61 | 63 | Under 11 | $233K |
| Fluorouracil Generic | 52 | 54 | 40 | $3,688 |
| Ketoconazole Generic | 41 | 51 | 29 | $905 |
| Fluocinonide Generic | 38 | 39 | 26 | $1,697 |
| Cosentyx Unoready Pen Secukinumab | 34 | 34 | Under 11 | $410K |
| Fluticasone Propionate Generic | 29 | 29 | 24 | $586 |
| Valacyclovir Valacyclovir Hcl | 26 | 46 | 15 | $1,136 |
| Clobetasol Propionate Generic | 25 | 25 | 20 | $2,041 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 21 | 21 | Under 11 | $150K |
| Metronidazole Generic | 21 | 25 | 16 | $1,350 |
| Dutasteride Generic | 20 | 60 | Under 11 | $684 |
Brand drugs: 321 claims; generic drugs: 712 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Brian A Reber $2,122 ($2,122 in general payments such as food, travel and fees) from 15 companies. The largest payer was Abbvie Inc. with $521.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 38 | $521 |
| Janssen Biotech, Inc. JNJ | 13 | $359 |
| Genzyme Corporation SNY | 11 | $326 |
| LEO Pharma Inc. | 11 | $213 |
| Incyte Corporation INCY | 8 | $197 |
| Galderma Laboratories, L.P. GALD.SW | 10 | $164 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $74.87 |
| UCB, Inc. UCB.BR | 3 | $61.92 |
| Arcutis Biotherapeutics, Inc. ARQT | 1 | $56.16 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $49.76 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.